Table 3.
Comparison between the OS and PFS of trials with chemotherapeutic agents in patients with prior chemotherapy experience.
| Reference | Prior Chemotherapy Drugs (Treatment Failure) | Second-Line Treatment | Overall Survival (OS) | Progression-Free Survival (PFS) |
|---|---|---|---|---|
| Belli et al. [29] | Gemcitabine | Trabectedin | 5.2 months | 1.9 months |
| Wang-Gillam et al. [30] | Gemcitabine | 1- Nanoliposomal irinotecan plus fluorouracil and folinic acid 2- Fluorouracil and folinic acid 3- Nanoliposomal irinotecan monotherapy |
1- 6.1 months 2- 4.2 months 3- 4.9 months |
NA |
| Wu et al. [24] | Gemcitabine | Lapatinib and capecitabine | 5.2 months | 2.6 months |
| Hurwitz et al. [25] | Gemcitabine | 1- Ruxolitinib plus capecitabine 2- Placebo plus capecitabine |
1- 4.5 months 2- 4.3 months |
NA |
| Makielski et al. [26] | Prior gemcitabine-containing therapy (n = 15 out of 24). Prior pancreatectomies (n = 2 out of 24). Previous pancreatic radiotherapy (n = 3 out of 24). | Sorafenib, oxaliplatin, and two days of high-dose capecitabine | 8.1 months | 6.0 months |
| Assenat et al. [31] | Gemcitabine | Cetuximab and trastuzumab | 4.6 months | 1.8 months |
| Ohkawa et al. [32] | Gemcitabine | 1- S-1 monotherapy 2- S-1 plus oxaliplatin |
1- 6.9 months 2- 7.4 months |
1- 2.8 months 2- 3.0 months |
| Kordes et al. [27] | Prior gemcitabine-based chemotherapy (n = 18 out of 31). Palliative setting (n = 11 out of 31). Adjuvant (n = 6 out of 31; 5 patients with chemotherapy free interval <6months and 1 as part of neoadjuvant chemoradiotherapy). | Capecitabine and everolimus | 8.9 months | 3.6 months |
| Herman et al. [19] | Gemcitabine | Gemcitabine and stereotactic body radiotherapy | 13.9 months | 7.8 months |
| Lombard-Bohas et al. [34] | Two or less prior cytotoxic chemotherapy regimens, interferon, radio labeled somatostatin analog, prior octreotide and/or continued octreotide at a stable dose, or prior hepatic arterial therapies for liver metastasis | Temsirolimus and bevacizumab | 34.0 months | 13.2 months |
| Ettrich et al. [35] | Gemcitabine | Docetaxel and oxaliplatin | 10.1 months | 1.82 months |
| Ueno et al. [36] | Gemcitabine | 1- S-1 plus leucovorin 2- S-1 monotherapy |
1- 6.3 months 2- 6.1 months |
1- 3.8 months 2- 2.7 months |
| Postlewait et al. [22] | Gemcitabine | Gemcitabine and cisplatin | 35.5 months | NA |
| Ioka et al. [37] | Gemcitabine | 1- S-1 plus irinotecan 2- S-1 alone |
1- 6.8 months 2- 5.8 months |
1- 3.5 months 2- 1.9 months |